Puma Biotechnology Inc Stock News

Puma Biotech (PBYI) delivered earnings and revenue surprises of 950% and 11.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Puma Biotech (PBYI) delivered earnings and revenue surprises of 950% and 11.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Celldex (CLDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Puma Biotech (PBYI) Q1 loss narrows while sales come in line with estimates. PBYI's stock declines in the after-market trading session following the news.

Puma Biotech (PBYI) Q1 loss narrows while sales come in line with estimates. PBYI's stock declines in the after-market trading session following the news.

Puma Biotech (PBYI) delivered earnings and revenue surprises of 38.46% and 0.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director of Investor Relations Alan Auerbach - Chairman,

Puma Biotech (PBYI) delivered earnings and revenue surprises of 38.46% and 0.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -300% and 97.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Puma Biotech (PBYI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

During the last session, Puma Biotechnology Inc. (NASDAQ:PBYI)’s traded shares were 0.39 million, with the beta value of the company hitting 0.96. At the end of the trading day, the stock’s price was $2.63, reflecting an intraday loss of -9.31% or -$0.27. The 52-week high for the PBYI share is $11.95, that puts it down … Is Puma Biotechnology Inc. (NASDAQ: PBYI) Stock On Course For Another Boom Or Bust? Read More »

Puma Biotechnology (PBYI) beats on earnings and sales for the fourth quarter of 2021. PBYI???s shares increase in after-market trading session following the news.

Puma Biotechnology (PBYI) beats on earnings and sales for the fourth quarter of 2021. PBYI???s shares increase in after-market trading session following the news.